Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.Ziad Bakouny, Toni K. Choueiri, Anil Kapoor et al.|Journal of Clinical Oncology|2020Cited by 20
The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).Andrew Schmidt, Toni K. Choueiri, Wanling Xie et al.|Journal of Clinical Oncology|2021Cited by 13
Comparison of outcomes for Hispanic and non‐Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma DatabaseKripa Guram, Rana R. McKay, Jiaming Huang et al.|Cancer|2024Cited by 3
Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.Steven Yip, Daniel Yick Chin Heng, José Manuel Ruiz Morales et al.|Journal of Clinical Oncology|2016Cited by 1
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).José Manuel Ruiz Morales, Daniel Yick Chin Heng, J. Connor Wells et al.|Journal of Clinical Oncology|2016Cited by 1